apremilast,zasocitinib,deucravacitinib
amgen,takeda,bms
['poetyk,pso-1', 'psoriasis', 'tak-279', 'ndi-034858', '$bmy', '$tak']
cross-trial comparison of $tak's tyk2 inhibitor and $bmy's sotyktu in psoriasis. the pasi-100 response with the highest dose of tak-279 is particularly impressive, but the drugs look similar on pga0/1 score. awaiting more info on adverse events from the presentation #aad2023 
News Editor for Vantage covering biopharma and medtech; cat lover; banana run winner